Leerink raised its price target for Universal Health to $140 citing the company's "strong" Q1 results. The firm keeps an Outperform rating on the name.
Barclays analyst Andrew Mok raised the firm's price target on Universal Health to $189 from $181 and keeps an Equal Weight rating on the shares post the Q1 report. The company posted broad pricing strength and strong acute inpatient volumes, which drove a big EBITDA beat, the analyst tells investors in a research note.
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSImpinj (PI) up... To see the rest of the story go to thefly.com. See Story Here